Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone

Susumu Ogawa, Kazuhisa Takeuchi, Sadayoshi Ito

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


We monitored the change in plasma ANP and BNP levels (as markers for left ventricular dysfunction (LVD)) in DM2 patients treated with pioglitazone (Pio) for 4 weeks. Thirty DM2 patients with no sign of heart failure were treated with Pio (15mg/day), and their plasma ANP (normal levels ≦43 pg/ml) and BNP levels (normal levels ≦ 18.4 pg/ml) were examined. We also examined those levels in no drug-treatment group (n=10) as well as buformine treatment group (n=10). Among these groups, there were no significant differences in clinical profiles related to DM control. Pio treatment was terminated when BNP (above 100 pg/ml) and ANP levels (above 50 pg/ml) suggested the left ventricular dysfunction (LVD). The patients (n=12) whose BNP levels reached to the LVD-positive levels showed the basal BNP levels above the normal upper limit (18 pg/ml), while the rest of subjects (n=18) whose basal BNP levels within normal limits did not showed the LVD-positive levels in the Pio-treatment. On the other hand basal ANP levels did not predict the development to LVD. In conclusion, BNP levels are suggested to be a good marker of Pio-induced LVD, and the Pio treatment of DM2 patients with BNP levels above the normal limit should be carefully carried out by monitoring BNP levels.

Original languageEnglish
Pages (from-to)3993-3996
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Issue number8
Publication statusPublished - 2003 Aug 1


Dive into the research topics of 'Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone'. Together they form a unique fingerprint.

Cite this